BCR and B-cell chronic lymphocytic leukemia: In this review, five patients developed RT–PBL after ibrutinib, raising the possibility that CLL transforms to RT–PBL as a mechanism of resistance to BCR inhibition or that minor RP–PBL subclones might have been present at treatment initiation potentially selected with a BCR inhibition.